Britons are among the happiest people in the world – and are becoming more cheerful, according to an annual United Nations survey.
The seventh annual World Happiness Report placed the UK 15th in the 156-country ranking, just ahead of Ireland.
The list, based on research conducted between 2016 and 2018, is published on International Day of Happiness.
Finland, Denmark and Norway were the happiest nations while South Sudan replaced Burundi as the least happy.
International Day of Happiness began in 2012 when all countries of the United Nations agreed to create an official, annual fixture on the calendar.
The list is published by the London-based Action for Happiness charity and sees survey respondents place the status of their lives on a scale ranging from 0 to 10.
To read more about this on the BBC website, go to: https://www.bbc.com/news/uk-47637378?ns_mchannel=social&ns_campaign=bbcnews&ocid=socialflow_twitter&ns_source=twitter
According to Manchester University, UK, a new class of drugs, called PARG inhibitors, have the ability of treating ovarian cancer and even stopping cancer cells from growing.
Published in the Journal Cancer Cell, a study funded by the Cancer Research UK and Wellcome Trust showed that treating ovarian cancer may come sooner than you think. According to the researchers at The University of Manchester the drugs, PARG inhibitors, can kill ovarian cancer cells by targeting weaknesses within their ability to copy their DNA.
The first-in-class PARG inhibitor PDD00017273, was discovered in the Drug Discovery Unit at the Cancer Research UK Manchester Institute, part of The University of Manchester, as part of a targeted program to discover PARG inhibitors for the clinic.
To read more about this on the Health Europa website, go to: https://www.healtheuropa.eu/treating-ovarian-cancer/90840/
This program is currently being progressed through a collaboration with IDEAYA Biosciences, Inc., an oncology-focused biotechnology company dedicated to the discovery of breakthrough synthetic lethality medicines and immuno-oncology therapies.